Characteristics of patients receiving first HCT for BPDCN between 2007 and 2018, registered with the CIBMTR
| Characteristic . | MAC . | RIC/NMA . | Total . |
|---|---|---|---|
| Patients, n | 84 | 80 | 164 |
| Centers, n | 47 | 49 | 78 |
| Age (y) at HCT, n (%) | |||
| Median (min-max) | 49 (18-70) | 65 (20-78) | 58 (18-78) |
| 18-29 | 15 (18) | 3 (4) | 18 (11) |
| 30-39 | 16 (19) | 5 (6) | 21 (13) |
| 40-49 | 13 (16) | 2 (3) | 15 (9) |
| 50-59 | 26 (31) | 12 (15) | 38 (23) |
| 60-69 | 14 (17) | 40 (50) | 54 (33) |
| ≥70 | 0 (<1) | 18 (23) | 18 (11) |
| Reporting track, n (%) | |||
| TED | 60 (71) | 65 (81) | 125 (76) |
| CRF | 24 (29) | 15 (19) | 39 (24) |
| Recipient sex, n (%) | |||
| Male | 60 (71) | 66 (83) | 126 (77) |
| Female | 24 (27) | 14 (18) | 38 (23) |
| Race, n (%) | |||
| Caucasian | 65 (77) | 60 (75) | 125 (76) |
| African-American | 11 (13) | 7 (9) | 18 (11) |
| Asian | 2 (2) | 3 (4) | 5 (3) |
| Not reported | 6 (7) | 10 (13) | 16 (10) |
| Karnofsky performance status score, n (%) | |||
| <90 | 27 (32) | 31 (39) | 58 (35) |
| ≥90 | 56 (67) | 49 (61) | 105 (64) |
| Not reported | 1 (1) | 0 (<1) | 1 (1) |
| HCT-CI , n (%) | |||
| 0 | 27 (32) | 16 (20) | 43 (26) |
| 1-2 | 24 (29) | 26 (33) | 50 (31) |
| ≥3 | 32 (38) | 36 (45) | 68 (42) |
| Not reported | 1 (1) | 2 (3) | 3 (2) |
| Disease status before HCT, n (%) | |||
| Primary induction failure | 10 (12) | 10 (13) | 20 (12) |
| CR1 | 62 (74) | 59 (74) | 121 (74) |
| CR2 | 10 (12) | 7 (9) | 17 (10) |
| Relapse | 2 (2) | 4 (5) | 6 (4) |
| Time (mo) from diagnosis to HCT, n (%) | |||
| <6 | 50 (60) | 32 (40) | 82 (50) |
| 6-12 | 29 (35) | 37 (46) | 66 (40) |
| >12 | 5 (6) | 11 (14) | 16 (10) |
| Donor type, n (%) | |||
| HLA-identical sibling | 24 (29) | 17 (21) | 41 (25) |
| Other related | 12 (14) | 16 (20) | 28 (17) |
| Well-matched unrelated (8 of 8) | 34 (41) | 31 (39) | 65 (40) |
| Partially matched unrelated (7 of 8) | 3 (4) | 7 (9) | 10 (6) |
| Mismatched unrelated (≤6 of 8) | 1 (1) | 0 (<1) | 1 (1) |
| Unrelated (matching unknown) | 3 (4) | 5 (6) | 8 (5) |
| Cord blood | 7 (8) | 4 (5) | 11 (7) |
| Donor/recipient CMV serostatus, n (%) | |||
| +/+ | 29 (35) | 27 (34) | 56 (34) |
| +/− | 8 (10) | 11 (14) | 19 (12) |
| −/+ | 22 (26) | 24 (30) | 46 (28) |
| −/− | 23 (27) | 17 (21) | 40 (24) |
| Not reported | 2 (2) | 1 (1) | 3 (2) |
| Donor/recipient sex match, n (%) | |||
| M-M | 40 (48) | 42 (53) | 82 (50) |
| M-F | 10 (12) | 8 (10) | 18 (11) |
| F-M | 20 (24) | 24 (30) | 44 (27) |
| F-F | 14 (17) | 6 (8) | 20 (12) |
| Graft type, n (%) | |||
| BM | 9 (11) | 9 (11) | 18 (11) |
| Peripheral blood | 68 (81) | 67 (84) | 135 (82) |
| Cord blood | 7 (8) | 4 (5) | 11 (7) |
| TBI usage, n (%) | |||
| No | 40 (48) | 47 (59) | 87 (53) |
| Yes | 44 (52) | 33 (41) | 77 (47) |
| GVHD prophylaxis, n (%) | |||
| PTCy | 16 (19) | 18 (23) | 34 (21) |
| CNI + MMF w/wo others | 12 (14) | 23 (29) | 35 (21) |
| CNI + MTX w/wo others (not MMF or PTCy) | 47 (56) | 31 (39) | 78 (48) |
| CNI + others (not MMF, MTX, or PTCy) | 7 (8) | 4 (5) | 11 (7) |
| Other | 2 (2) | 4 (5) | 6 (4) |
| Year of HCT, n (%) | |||
| 2007 | 2 (2) | 0 (<1) | 2 (1) |
| 2008 | 1 (1) | 0 (<1) | 1 (1) |
| 2009 | 0 (<1) | 3 (4) | 3 (2) |
| 2010 | 2 (2) | 2 (3) | 4 (2) |
| 2011 | 8 (10) | 5 (6) | 13 (8) |
| 2012 | 7 (8) | 8 (10) | 15 (9) |
| 2013 | 9 (11) | 9 (11) | 18 (11) |
| 2014 | 11 (13) | 6 (8) | 17 (10) |
| 2015 | 9 (11) | 13 (16) | 22 (13) |
| 2016 | 12 (14) | 13 (16) | 25 (15) |
| 2017 | 12 (14) | 15 (19) | 27 (17) |
| 2018 | 11 (13) | 6 (8) | 17 (10) |
| Follow-up of survivors (mo), median (range) | 49 (12-121) | 49 (6-119) | 49 (6-121) |
| Characteristic . | MAC . | RIC/NMA . | Total . |
|---|---|---|---|
| Patients, n | 84 | 80 | 164 |
| Centers, n | 47 | 49 | 78 |
| Age (y) at HCT, n (%) | |||
| Median (min-max) | 49 (18-70) | 65 (20-78) | 58 (18-78) |
| 18-29 | 15 (18) | 3 (4) | 18 (11) |
| 30-39 | 16 (19) | 5 (6) | 21 (13) |
| 40-49 | 13 (16) | 2 (3) | 15 (9) |
| 50-59 | 26 (31) | 12 (15) | 38 (23) |
| 60-69 | 14 (17) | 40 (50) | 54 (33) |
| ≥70 | 0 (<1) | 18 (23) | 18 (11) |
| Reporting track, n (%) | |||
| TED | 60 (71) | 65 (81) | 125 (76) |
| CRF | 24 (29) | 15 (19) | 39 (24) |
| Recipient sex, n (%) | |||
| Male | 60 (71) | 66 (83) | 126 (77) |
| Female | 24 (27) | 14 (18) | 38 (23) |
| Race, n (%) | |||
| Caucasian | 65 (77) | 60 (75) | 125 (76) |
| African-American | 11 (13) | 7 (9) | 18 (11) |
| Asian | 2 (2) | 3 (4) | 5 (3) |
| Not reported | 6 (7) | 10 (13) | 16 (10) |
| Karnofsky performance status score, n (%) | |||
| <90 | 27 (32) | 31 (39) | 58 (35) |
| ≥90 | 56 (67) | 49 (61) | 105 (64) |
| Not reported | 1 (1) | 0 (<1) | 1 (1) |
| HCT-CI , n (%) | |||
| 0 | 27 (32) | 16 (20) | 43 (26) |
| 1-2 | 24 (29) | 26 (33) | 50 (31) |
| ≥3 | 32 (38) | 36 (45) | 68 (42) |
| Not reported | 1 (1) | 2 (3) | 3 (2) |
| Disease status before HCT, n (%) | |||
| Primary induction failure | 10 (12) | 10 (13) | 20 (12) |
| CR1 | 62 (74) | 59 (74) | 121 (74) |
| CR2 | 10 (12) | 7 (9) | 17 (10) |
| Relapse | 2 (2) | 4 (5) | 6 (4) |
| Time (mo) from diagnosis to HCT, n (%) | |||
| <6 | 50 (60) | 32 (40) | 82 (50) |
| 6-12 | 29 (35) | 37 (46) | 66 (40) |
| >12 | 5 (6) | 11 (14) | 16 (10) |
| Donor type, n (%) | |||
| HLA-identical sibling | 24 (29) | 17 (21) | 41 (25) |
| Other related | 12 (14) | 16 (20) | 28 (17) |
| Well-matched unrelated (8 of 8) | 34 (41) | 31 (39) | 65 (40) |
| Partially matched unrelated (7 of 8) | 3 (4) | 7 (9) | 10 (6) |
| Mismatched unrelated (≤6 of 8) | 1 (1) | 0 (<1) | 1 (1) |
| Unrelated (matching unknown) | 3 (4) | 5 (6) | 8 (5) |
| Cord blood | 7 (8) | 4 (5) | 11 (7) |
| Donor/recipient CMV serostatus, n (%) | |||
| +/+ | 29 (35) | 27 (34) | 56 (34) |
| +/− | 8 (10) | 11 (14) | 19 (12) |
| −/+ | 22 (26) | 24 (30) | 46 (28) |
| −/− | 23 (27) | 17 (21) | 40 (24) |
| Not reported | 2 (2) | 1 (1) | 3 (2) |
| Donor/recipient sex match, n (%) | |||
| M-M | 40 (48) | 42 (53) | 82 (50) |
| M-F | 10 (12) | 8 (10) | 18 (11) |
| F-M | 20 (24) | 24 (30) | 44 (27) |
| F-F | 14 (17) | 6 (8) | 20 (12) |
| Graft type, n (%) | |||
| BM | 9 (11) | 9 (11) | 18 (11) |
| Peripheral blood | 68 (81) | 67 (84) | 135 (82) |
| Cord blood | 7 (8) | 4 (5) | 11 (7) |
| TBI usage, n (%) | |||
| No | 40 (48) | 47 (59) | 87 (53) |
| Yes | 44 (52) | 33 (41) | 77 (47) |
| GVHD prophylaxis, n (%) | |||
| PTCy | 16 (19) | 18 (23) | 34 (21) |
| CNI + MMF w/wo others | 12 (14) | 23 (29) | 35 (21) |
| CNI + MTX w/wo others (not MMF or PTCy) | 47 (56) | 31 (39) | 78 (48) |
| CNI + others (not MMF, MTX, or PTCy) | 7 (8) | 4 (5) | 11 (7) |
| Other | 2 (2) | 4 (5) | 6 (4) |
| Year of HCT, n (%) | |||
| 2007 | 2 (2) | 0 (<1) | 2 (1) |
| 2008 | 1 (1) | 0 (<1) | 1 (1) |
| 2009 | 0 (<1) | 3 (4) | 3 (2) |
| 2010 | 2 (2) | 2 (3) | 4 (2) |
| 2011 | 8 (10) | 5 (6) | 13 (8) |
| 2012 | 7 (8) | 8 (10) | 15 (9) |
| 2013 | 9 (11) | 9 (11) | 18 (11) |
| 2014 | 11 (13) | 6 (8) | 17 (10) |
| 2015 | 9 (11) | 13 (16) | 22 (13) |
| 2016 | 12 (14) | 13 (16) | 25 (15) |
| 2017 | 12 (14) | 15 (19) | 27 (17) |
| 2018 | 11 (13) | 6 (8) | 17 (10) |
| Follow-up of survivors (mo), median (range) | 49 (12-121) | 49 (6-119) | 49 (6-121) |
CMV, cytomegalovirus; CNI, calcineurin inhibitors; CRF, comprehensive report form; Cy, cyclophosphamide; F, female; HCT-CI; HCT comorbidity index; M, male; max, maximum; MMF, mycophenolate mofetil; min, minimum; MTX, methotrexate; PTCy; posttransplant cyclophosphamide; TED, transplant essential data; w/wo, with/without.